The spread is real
Search three vendors for the same 5 mg vial and the price can range from under $20 to over $45. The spread is not random. The cheapest option is not automatically the best deal either. Here is what drives it, drawn from how the supply chain and testing actually work. These products are sold for research use only and are not approved for human consumption.
What you're paying for
Start with synthesis. Peptides are made by solid-phase synthesis, and yield and purity depend on the process and the scale. Business-to-business manufacturers, the CDMOs such as Bachem and PolyPeptide, operate at pharmaceutical scale and price accordingly. The retail vials most buyers see are several steps downstream. The scale gap is widening. In September 2025 PolyPeptide reported a milestone in its Malmö, Sweden expansion aimed at doubling solid-phase synthesis capacity at the site, per PolyPeptide's own announcement.
Then testing. A vendor that pays an independent lab to test each batch and publishes the COA carries a real cost that a vendor shipping untested powder does not. That cost shows up in the price.
Purity and content matter too. As independent labs note, two vials with the same label can differ in net peptide content. A higher price sometimes buys more actual peptide per vial, which makes a raw price comparison misleading. Comparing price per milligram of delivered peptide is closer to apples-to-apples, which is why we show a normalized $/mg figure where the data allows.
Why the cheapest vial is a warning sign
Across community and vendor research, an implausibly low price is one of the most-cited red flags. A vial priced far below the cost of synthesis plus testing implies something was skipped: testing, purity, or honest labeling. The widely referenced anchor is BPC-157 5 mg. As of early 2026, tested product from vendors that publish independent COAs commonly lists in roughly the $35–60 range. Prices far below that, or on a normalized basis well under about $3 per milligram, are more often treated as a signal to be cautious than as a bargain. These figures move with the market and should be read as a rough heuristic, not a fixed line.
This is not a claim that expensive always means better. Paying more guarantees nothing on its own. Price has to be read alongside testing and provenance, not by itself.
A regulatory note worth pricing in
None of these compounds is an FDA-approved drug, and the regulatory picture is actively shifting. In April 2026 the FDA removed a group of peptide bulk drug substances, BPC-157 among them, from Category 2 of its Section 503A list after the underlying nominations were withdrawn. It also scheduled Pharmacy Compounding Advisory Committee meetings, beginning July 23–24, 2026, to weigh whether certain peptides should be added to the 503A bulks list at all. This was reported by trade and legal press including Fierce Pharma and law firm Orrick, with the underlying lists maintained on the FDA's 503A bulk substances page. For buyers, the point is simple. The products discussed here remain research-use-only materials, not approved medicines, regardless of price.
How we present it
We aggregate vendor prices and, where independent test data exists, show it next to the price, attributed to the lab that produced it and never as our own verdict. The comparison is the point. Ranking is built from objective signals, and nothing on the page is paid placement.